Bisphosphonates do not alter the rate of secondary mineralization

Bone

Volumn 49, Issue 4, 2011, Pages 701-705

  Fuchs, Robyn K ^a,b   Faillace, Meghan E ^c   Allen, Matt R ^a,b   Phipps, Roger J ^d   Miller, Lisa M ^e   Burr, David B ^a,b,f  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c St Francis Hospital The Heart Center   (United States)

^d HUSSON UNIVERSITY   (United States)

^e BROOKHAVEN NATIONAL LABORATORY   (United States)

^f Indiana University Purdue University Indianapolis   (United States)

Author keywords

Animal model; Bisphosphonates; FTIRM; Mineralization; Trabecular bone

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CARBONIC ACID; COLLAGEN; FLUOROCHROME; PHOSPHATE; RISEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MINERAL; BONE MINERALIZATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; FEMALE; FEMUR NECK; FOURIER TRANSFORM INFRARED MICROSPECTROSCOPY; FOURIER TRANSFORM MASS SPECTROMETRY; NONHUMAN; TRABECULAR BONE;

ANIMALS; BODY WEIGHT; BONE DENSITY; CALCIFICATION, PHYSIOLOGIC; DIPHOSPHONATES; FEMALE; FEMUR NECK; RABBITS; SPECTROPHOTOMETRY, INFRARED;

EID: 80052303465     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.05.009     Document Type: Article

References (31)

1. Russell R.G., Xia Z., Dunford J.E., Oppermann U., Kwaasi A., Hulley P.A., et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 2007, 1117:209-257.
2. Abelson A., Ringe J.D., Gold D.T., Lange J.L., Thomas T. Longitudinal change in clinical fracture incidence after initiation of bisphosphonates. Osteoporos Int 2010, 21(6):1021-1029.
3. Watts N., Diab D. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrin Metab 2010, 95(4):1555-1565.
4. Benhamou C.L. Effects of osteoporosis medications on bone quality. Joint Bone Spine 2007, 74:39-47.
5. Roschger P., Fratzl P., Klaushofer K., Rodan G. Mineralization of cancellous bone after alendronate and sodium fluoride treatment: a quantitative backscattered electron imaging study on minipig ribs. Bone 1997, 20:393-397.
6. Fratzl P., Roschger P., Fratzl-Zelman N., Paschalis E.P., Phipps R., Klaushofer K. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume. Calcif Tissue Int 2007, 81:73-80.
7. Mashiba T., Mori S., Burr D.B., Komatsubara S., Cao Y., Manabe T., et al. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 2005, 23(SUPPL):36-42.
8. Burr D.B., Miller L., Grynpas M., Li J., Boyde A., Mashiba T., et al. Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs. Bone 2003, 33:960-969.
9. Boivin G.Y., Chavassieux P.M., Santora A.C., Yates J., Meunier P.J. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000, 27:687-694.
10. Ruffoni D., Fratzl P., Roschger P., Phipps R., Klaushofer K., Weinkamer R. Effect of temporal changes in bone turnover on the bone mineralization density distribution: a computer simulation study. J Bone Miner Res 2008, 23:1905-1914.
11. Durchschlag E., Paschalis E.P., Zoehrer R., Roschger P., Fratzl P., Recker R., et al. Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate. J Bone Miner Res 2006, 21:1581-1590.
12. Boivin G., Meunier P.J. Changes in bone remodeling rate influence the degree of mineralization of bone. Connect Tissue Res 2002, 43:535-537.
13. Miller L., Dumas P., Jamin N., Teillaud J., Miklossy J., Forro L. Combining IR spectroscopy with fluorescence imaging in a single microscope: biomedical applications using a synchrotron infrared source. Rev Scientif Instrum 2002, 73:1357-1360.
14. Miller L.M., Vairavamurthy V., Chance M.R., Mendelsohn R., Paschalis E.P., Betts F., et al. In situ analysis of mineral content and crystallinity in bone using infrared micro-spectroscopy of the nu(4) PO(4)(3-) vibration. Biochim Biophys Acta 2001, 1527:11-19.
15. Paschalis E.P., Betts F., DiCarlo E., Mendelsohn R., Boskey A.L. FTIR microspectroscopic analysis of normal human cortical and trabecular bone. Calcif Tissue Int 1997, 61:480-486.
16. Fuchs R.K., Phipps R.J., Burr D.B. Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats. J Bone Miner Res 2008, 23:1689-1697.
17. Fuchs R.K., Phipps R.J., Burr D.B. Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats. J Bone Miner Res 2008, 23:1689-1697.
18. Gertz B.J., Holland S.D., Kline W.F., Matuszewski B.K., Freeman A., Quan H., et al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 1995, 58:288-298.
19. Laitinen K., Patronen A., Harju P., Loyttyniemi E., Pylkkanen L., Kleimola T., et al. Timing of food intake has a marked effect on the bioavailability of clodronate. Bone 2000, 27:293-296.
20. Aparicio S., Doty S.B., Camacho N.P., Paschalis E.P., Spevak L., Mendelsohn R., et al. Optimal methods for processing mineralized tissues for Fourier transform infrared microspectroscopy. Calcif Tissue Int 2002, 70:422-429.
21. Carr G., Reffner J., GP W Performance of an infrared microspectrometer at the NSLS. Rev Sci Instr 1995, 66:1490-1492.
22. Reffner J.A., Martoglio P.A., Williams G.P. Fourier transform infrared microscopical analysis with synchrotron radiation: the microscope optics and system performance. Rev Scientif Instrum 1995, 66:1298-1302.
23. Roschger P., Rinnerthaler S., Yates J., Rodan G.A., Fratzl P., Klaushofer K. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 2001, 29:185-191.
24. Boivin G., Meunier P.J. Effects of bisphosphonates on matrix mineralization. J Musculoskelet Neuronal Interact 2002, 2:538-543.
25. Grynpas M. Age and disease-related changes in the mineral of bone. Calcif Tissue Int 1993, 53(SUPPL 1):S57-S64.
26. Boivin G., Meunier P.J. The degree of mineralization of bone tissue measured by computerized quantitative contact microradiography. Calcif Tissue Int 2002, 70:503-511.
27. Zoehrer R., Roschger P., Paschalis E.P., Hofstaetter J.G., Durchschlag E., Fratzl P., et al. Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women. J Bone Miner Res 2006, 21:1106-1112.
28. Borah B., Dufresne T.E., Ritman E.L., Jorgensen S.M., Liu S., Chmielewski P.A., et al. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone 2006, 39:345-352.
29. Fuchs R.K., Allen M.R., Ruppel M.E., Diab T., Phipps R.J., Miller L.M., et al. In situ examination of the time-course for secondary mineralization of Haversian bone using synchrotron Fourier transform infrared microspectroscopy. Matrix Biol 2008, 27:34-41.
30. Marotti G., Favia A., Zallone A.Z. Quantitative analysis on the rate of secondary bone mineralization. Calcif Tissue Res 1972, 10:67-81.
31. Huang R.Y., Miller L.M., Carlson C.S., Chance M.R. In situ chemistry of osteoporosis revealed by synchrotron infrared microspectroscopy. Bone 2003, 33:514-521.